News Brief
Summary
Novo Nordisk has reduced the direct-to-consumer prices for its weight loss drug Wegovy and diabetes drug Ozempic. A temporary introductory offer for new patients has also been launched. These moves follow recent agreements between the Trump administration, Novo Nordisk, and Eli Lilly aimed at improving drug accessibility and affordability.
Key Points
- Price Reduction: The monthly price for existing cash-paying patients of Wegovy and Ozempic is lowered to $349 from $499. (The highest Ozempic dose remains $499).
- Introductory Offer: New cash-paying patients can get the two lowest doses for $199 per month for the first two months. This offer ends March 31.
- Administration Deal: Follows recent agreements with the Trump administration to make GLP-1 drugs more accessible and affordable, including through the new TrumpRx website.
- Competitor Action: Rival Eli Lilly also recently announced price reductions on its direct-to-consumer platform, LillyDirect.
- Availability: Novo Nordisk’s new offers are available through its websites, NovoCare pharmacy, and partners like Costco and WeightWatchers.
新闻简报
总结
诺和诺德公司已降低其减肥药Wegovy和糖尿病药Ozempic的直接面向消费者的价格。同时为新的自费患者推出了临时入门优惠。这些举措是在特朗普政府与诺和诺德及礼来公司达成旨在提高药物可及性和可负担性的协议之后进行的。
关键点
- 价格下调： 现有自费患者使用Wegovy和Ozempic的月费从499美元降至349美元。（Ozempic最高剂量仍为499美元）。
- 入门优惠： 新的自费患者在治疗的头两个月可以每月199美元的价格获得两种最低剂量。此优惠于3月31日结束。
- 政府协议： 此前特朗普政府与诺和诺德及礼来公司达成协议，旨在通过新的TrumpRx网站等方式提高GLP-1类药物的可及性和可负担性。
- 竞争对手行动： 竞争对手礼来公司近期也宣布在其直接面向消费者的平台LillyDirect上降价。
- 获取渠道： 诺和诺德的新优惠可通过其官方网站、NovoCare药房以及Costco、WeightWatchers等合作伙伴获取。
Original Article Link: https://www.cnbc.com/2025/11/17/novo-nordisk-cash-prices-wegovy-ozempic.html